Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN